Uterine Cancer

Uterine cancer is cancer that starts in the uterus, also known as the womb. It's a type of gynecological cancer. Early detection is important for successful treatment.

Condition

What people with Uterine Cancer report

Every report comes from a Lived member, sent anonymously.

Have you had Hysterectomy for Uterine Cancer?

NameHow it went

About Uterine Cancer

What It Is

Uterine cancer is cancer that starts in the uterus (the womb). Most cases are endometrial cancer, which begins in the endometrium, the lining that builds up and sheds with the menstrual cycle. A much rarer group, uterine sarcomas, starts in the muscle wall or supporting tissue of the uterus. Sarcomas tend to be more aggressive and harder to treat. Endometrial cancer is the most common cancer of the female reproductive organs in the United States. It mainly affects people after menopause, at an average age of about 60, and is uncommon before 45. Its most typical early sign is abnormal vaginal bleeding, especially bleeding after menopause. Because that sign tends to appear early, about two-thirds of cases are found while the cancer is still confined to the uterus, when it can usually be cured.

Causes & Risk Factors

Many endometrial cancers are linked to long-term exposure of the uterine lining to estrogen without enough progesterone to balance it. Estrogen makes the lining grow, and prolonged growth without that balance raises the chance of abnormal cells developing. Obesity and weight gain in adulthood raise risk, partly because fat tissue makes estrogen. Estrogen-only hormone therapy after menopause raises risk in someone who still has a uterus, which is why a progestin is added for them; combined estrogen-progestin therapy does not raise endometrial cancer risk. Starting periods early, reaching menopause late, never having been pregnant, polycystic ovary syndrome, type 2 diabetes and metabolic syndrome are also associated with higher risk. Endometrial hyperplasia, an overgrowth of the lining, is not cancer, but some forms can progress to it. Tamoxifen, a medicine used to treat or prevent breast cancer, acts like estrogen on the uterus. Taking it for more than two years raises the risk of endometrial cancer, especially after menopause, and it is also a risk factor for uterine sarcoma, as is past radiation to the pelvis. Inherited factors matter for a smaller group. Lynch syndrome, a genetic condition that also raises the risk of colon cancer, greatly increases endometrial cancer risk, and having a mother, sister or daughter with endometrial cancer raises it too. Combined birth control pills lower the risk, with protection that lasts for years after stopping, and pregnancy and physical activity are associated with lower risk. A risk factor is not a cause: some people with several never develop uterine cancer, and some people with none do.

How It's Diagnosed

There is no routine screening test for uterine cancer in people at average risk, and a Pap test, which screens for cervical cancer, is not designed to find it. Diagnosis usually begins because of symptoms, most often unexpected bleeding. A clinician asks about the bleeding, other symptoms and family history and does a pelvic exam. A transvaginal ultrasound, in which a small probe placed in the vagina uses sound waves to picture the uterus, can show whether the lining is thicker than expected or whether there is a mass. Ultrasound can raise or lower suspicion, but only a tissue sample confirms cancer. The most common sample is an endometrial biopsy, done in the office by passing a thin, flexible tube through the cervix and suctioning a small piece of lining. It takes about a minute and usually feels like strong menstrual cramps. If that sample is too small or unclear, a D&C (dilation and curettage, in which the cervix is gently widened and tissue is scraped from the lining) may be done, sometimes with hysteroscopy, a thin lighted scope used to look inside the uterus. If cancer is found, the lab reports its type and grade (how abnormal the cells look). The tumor is also tested for mismatch repair (MMR) defects, faults in the cells' system for fixing DNA errors. These results help guide treatment, including whether immunotherapy is likely to work, and can flag possible Lynch syndrome, in which case genetic testing is offered because relatives may share the risk. CT, MRI or PET scans may be used to look for spread. The stage, which describes how far the cancer has spread, is usually settled during surgery, when the uterus and lymph nodes are examined under the microscope.

Treatment Options

Treatment depends on the type of cancer, its stage and grade, the tumor's molecular features, overall health and whether a future pregnancy matters. Care is often led by a gynecologic oncologist, a surgeon who specializes in cancers of the reproductive organs. For most people the main treatment is surgery: a total hysterectomy (removal of the uterus and cervix), usually with removal of both ovaries and fallopian tubes, plus a check of nearby lymph nodes. Many surgeons use sentinel lymph node mapping, injecting a dye to find the first nodes the uterus drains to; if those are clear, no further nodes are removed. Surgery is often done laparoscopically or robotically through small incisions, with survival similar to open surgery and usually a same-day or next-day discharge. For early, lower-risk endometrial cancer, surgery is often the only treatment needed. A hysterectomy ends the ability to become pregnant, and removing the ovaries before menopause brings on menopause right away. For some premenopausal people with low-stage, non-aggressive cancer, keeping the ovaries may be an option to discuss. When the cancer has features that raise the chance of it coming back, more treatment follows. Vaginal brachytherapy places a radiation source in the vagina for short sessions to treat its upper part, where the uterus was attached. External beam radiation treats the wider pelvis, usually five days a week for four to six weeks. Chemotherapy, typically carboplatin and paclitaxel, is used mainly when cancer has spread beyond the uterus or comes back. For advanced or recurrent endometrial cancer, immunotherapy has become an important option. Checkpoint inhibitors such as pembrolizumab (Keytruda) and dostarlimab (Jemperli) release a brake on the immune system so it can attack cancer cells, and they can be added to chemotherapy. They help most when the tumor has a mismatch repair defect: in one large trial, adding dostarlimab to chemotherapy lowered the risk of the cancer worsening or causing death by about 70% in that group over roughly two years. The trade-off is that the immune system can also attack healthy organs. For tumors without that defect, pembrolizumab combined with lenvatinib (Lenvima), a targeted pill, is an option after earlier treatment. Hormone therapy, most often a progestin (a medicine that acts like progesterone), is used for advanced or recurrent cancers, especially those with hormone receptors, and for people who cannot have surgery. For selected early, low-grade endometrial cancer in someone who hopes to become pregnant, a progestin, often released by a levonorgestrel intrauterine device (IUD) placed in the uterus, can be used instead of immediate hysterectomy. Uterine sarcomas are also treated mainly with surgery, sometimes followed by chemotherapy, radiation or hormone therapy.

What to Expect

The outlook depends most on how far the cancer has spread when it is found. Five-year relative survival, which compares people with the cancer to the general population, is about 96% for endometrial cancer confined to the uterus, about 72% when it has reached nearby tissues or lymph nodes, and about 22% when it has spread to distant organs such as the lungs, liver or bones. These figures come from people diagnosed several years ago, describe groups rather than individuals, and do not apply to uterine sarcoma. Recovery takes about three to four weeks after minimally invasive hysterectomy and four to six weeks after open surgery. Longer-term effects depend on the treatment. Surgical menopause can bring hot flashes, night sweats and vaginal dryness, and raises the long-term risk of bone thinning. Removing pelvic lymph nodes, especially when radiation follows, can lead to lymphedema, a lasting swelling of the legs or genital area that specialized physical therapists can help manage. Radiation can leave the vagina drier, shorter or narrower, which can make sex painful, and this is worth raising with the care team. After treatment, follow-up visits with a pelvic exam are typically every three to six months for the first two to three years, then every six to twelve months. If endometrial cancer returns, it usually does so within the first few years, and most recurrences are found because of symptoms rather than routine scans, so reporting changes matters. The metabolic factors that raise endometrial cancer risk also affect the heart, and heart disease is the most common cause of death among people with endometrial cancer, so attention to blood pressure, blood sugar and physical activity stays important after treatment.

When to Seek Help

See a clinician about any vaginal bleeding or spotting after menopause, and before menopause about bleeding between periods, unusual vaginal discharge, or pelvic pain or pressure that is new or persistent. These symptoms often have other causes, but checking them is how uterine cancer is usually found early. If you take tamoxifen, report any vaginal bleeding as soon as possible. If you have Lynch syndrome or a strong family history of endometrial or colon cancer, ask about genetic counseling and a monitoring plan. After treatment, contact your care team right away, rather than waiting for the next visit, about new bleeding from the vagina, bladder or rectum; new pain in the pelvis, hips, belly or back; unexplained weight loss; a cough or shortness of breath; or swelling in the belly or legs. During immunotherapy, report any new symptom promptly, because immune side effects can become serious.

Questions to Ask Your Doctor

  1. 1.What type and grade of uterine cancer do I have, and what stage do you expect it to be?
  2. 2.Was my tumor tested for mismatch repair defects, and should I or my relatives be tested for Lynch syndrome?
  3. 3.Will I need treatment after surgery, and what would radiation, chemotherapy or immunotherapy add in my situation?
  4. 4.If I want to keep the option of pregnancy or keep my ovaries, is that safe for my type of cancer?
  5. 5.What long-term effects should I prepare for, and what will my follow-up schedule look like?

Last reviewed • Oct 2026

Educational content, not medical advice.